1.
Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Apr. 16];6(6):s79. Available from: https://skin.dermsquared.com/skin/article/view/1837